Kimberly Southam-Gerow
Psychiatric/Mental Health · Richmond, VANPI 1598316424
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 400 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,067 and has fallen 54.3% since, to $945 in 2025. Among psychiatric/mental health clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $19.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Alkermes, Inc.$674
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$667
- Neurocrine Biosciences, Inc.$516
- Otsuka America Pharmaceutical, Inc.$390
- plus $3K from 19 others
What the payments were for
- Food & beverage$7,654100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 140 | $1,643 |
| Johnson & Johnson | 33 | $1,075 |
| Alkermes, Inc. | 30 | $674 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 32 | $667 |
| Neurocrine Biosciences, Inc. | 21 | $516 |
| Otsuka America Pharmaceutical, Inc. | 15 | $390 |
| Lundbeck LLC | 18 | $361 |
| Axsome Therapeutics, Inc. | 7 | $355 |
| Corium, LLC | 17 | $335 |
| Neos Therapeutics, LP | 12 | $257 |
| Bausch Health US, LLC | 12 | $250 |
| Vanda Pharmaceuticals Inc. | 11 | $247 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $230 |
| Ironshore Pharmaceuticals Inc. | 8 | $172 |
| Sunovion Pharmaceuticals Inc. | 11 | $143 |
| Noven Therapeutics, LLC | 4 | $53 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Avanir Pharmaceuticals, Inc. | 2 | $43 |
| Eisai Inc. | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 2 | $36 |
| Collegium Pharmaceutical, Inc. | 2 | $32 |
| Merck | 2 | $32 |
| Biogen | 1 | $25 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,654 in reported general payments places this provider in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 26 | $30,955 |
| Duloxetine Hcl | 27 | $2,659 |
| Bupropion XlBupropion Hcl | 20 | $580 |
| Buspirone Hcl | 18 | $136 |
| Clonazepam | 24 | $132 |
| Trazodone Hcl | 20 | $116 |
| Pregabalin | 11 | $108 |
| Sertraline Hcl | 15 | $103 |
| Lamotrigine | 16 | $87 |
| Hydroxyzine Pamoate | 11 | $53 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $1,075 | $30,95526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,003 psychiatric/mental health providers in Virginia.
Other psychiatric/mental health in Richmond
- Tonjanika BoydRichmond$40K
- Kirby PatmonRichmond$36K
- Abbie SmithRichmond$14K
- Thomas MamalakisRichmond$12K
- Monica MeyerRichmond$11K
- Vicky SpillerRichmond$10K
- Charles McDonoughRichmond$7K
- Nympha DalgadoRichmond$7K
- Justin RayChesapeake$127K
- Katia HallChesapeake$88K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.